论文部分内容阅读
目的:探讨化疗联合乌苯美司治疗对恶性肿瘤患者免疫功能的影响。方法:采用FCM法分别对150例行化疗联合乌苯美司辅助治疗和150例单用化疗治疗的恶性肿瘤患者外周血中T淋巴细胞亚群和自然杀伤(natural killer,NK)细胞进行检测。结果:化疗联合乌苯美司治疗组患者外周血中CD3+、CD4+T淋巴细胞和NK细胞(CD3-/CD16+CD56+)所占的比例及CD4+/CD8+的比值明显高于单用化疗(对照)组,而CD8+T细胞所占比例则有所下降,低于对照组,差异均有统计学意义(P<0.05)。结论:乌苯美司能够有效提高化疗后患者机体的免疫功能。
Objective: To investigate the effect of chemotherapy combined with ubenimex on immune function in patients with malignant tumor. Methods: Peripheral blood T lymphocyte subsets and natural killer (NK) cells were detected by FCM in 150 patients with malignant tumor treated with chemotherapy and ubenimex adjuvant and 150 patients with chemotherapy alone. Results: The proportion of CD3 +, CD4 + T lymphocytes and NK cells (CD3- / CD16 + CD56 +) and the ratio of CD4 + / CD8 + in peripheral blood of patients treated with chemotherapy and ubenimex were significantly higher than those of chemotherapy alone ) Group, while the proportion of CD8 + T cells decreased, lower than the control group, the difference was statistically significant (P <0.05). Conclusion: Ubenimex can effectively improve the immune function of patients after chemotherapy.